Publications

EuroSpA Publication X1

Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing. Click here to access full article

EuroSpA Publication B2

Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritis Click here to access full article

EuroSpA Publication D8.3

Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial SpondyloarthritiDefining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis Click here to access full article [...]

EuroSpA publication X2

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study Click here to access full article

EuroSpA publication 8.2

The relationship between lifestyle factors and outcome of treatment with TNFα inhibitors in axial spondyloarthritis – results from 14 European countries Click here to access full article

EuroSpA publication B9

Sacroiliac joint involvement in psoriatic arthritis – MRI, radiographic and clinical findings in 581 European routine care patients Click here to access full article

EuroSpA publication D2.2

Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation study Click here to access full article

EuroSpA publication A1.4

Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network Click here to access full article

EuroSpA publication A2.2

Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe Click here to access full article

EuroSpA publication B0

Imaging in a cohort of real-world patients with spondyloarthritis from five European countries – protocol for the European Spondyloarthritis Research Collaboration Network (EuroSpA) imaging project Click here to access full article

EuroSpA publication D2.1

Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased Click here to access full article

EuroSpA publication U1.1

Challenge of missing data in observational studies: investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritis Click here to access full article

EuroSpA publication D4.1

Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries Click here to access full article

EuroSpA publication A1.5

Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis Click here to access full article

EuroSpA publication A4.1

Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey Click here to access full article

EuroSpA publication D8.2

Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European  rheumatology registries Click here to access full article

EuroSpA publication BX.2

Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarthritis Click here to access full article

EuroSpA publication BX.1

Effect of Online Training on the Reliability of Assessing Sacroiliac Joint Radiographs in Axial Spondyloarthritis: A Randomized, Controlled Study Click here to access full article

EuroSpA publication 4.3

Comparing DAPSA, DAPSA28, and DAS28-CRP in PatientsWith Psoriatic Arthritis Initiating a First Tumor NecrosisFactor Inhibitor Across Nine European Countries Click here to access full article

Go to Top